MedTrace Logo

Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis

NCT02437461 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2017-10-30

No results posted yet for this study

Summary

This prospective randomised controlled single blind trial comparing the relapse rate in 6 months for 20 mg versus 40 mg intraarticular triamcinolone hexacetonide (Lederspan®) for knee synovitis in patients with rheumatoid arthritis (RA) and psoriatic artritis (PsoA) is performed to find the optimal dose to use.

Conditions

  • Arthritis of the Knee

Interventions

DRUG

Triamcinolone hexacetonide

intraarticular knee injection

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Tomas Weitoft, MD, PhD · Center for Research and Development Uppsala University/Region Gavleborg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-09-30
Completion
2018-06-20

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437461 on ClinicalTrials.gov